Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Hits Expectations

Anixa Biosciences (NASDAQ:ANIX) announced its quarterly earnings results on Monday. The company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09), Zacks reports.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $3.28 on Wednesday. The firm has a market capitalization of $107.98 million, a PE ratio of -9.37 and a beta of 0.49. The stock’s fifty day moving average is $3.93 and its 200 day moving average is $3.60. Anixa Biosciences has a fifty-two week low of $2.07 and a fifty-two week high of $5.46.

Analysts Set New Price Targets

ANIX has been the topic of several recent research reports. Zacks Research cut Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Wall Street Zen lowered shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Finally, D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Friday, December 12th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $9.00.

Institutional Investors Weigh In On Anixa Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC bought a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $33,000. Northwestern Mutual Wealth Management Co. grew its holdings in Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after purchasing an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. purchased a new stake in Anixa Biosciences in the 2nd quarter worth about $37,000. Marshall Wace LLP bought a new stake in Anixa Biosciences in the second quarter worth about $39,000. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of Anixa Biosciences during the third quarter valued at approximately $51,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.